Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Dermal Cell News 4.32 September 24, 2018 | |
 | |
| |
TOP STORYOlfactory Receptor OR2AT4 Regulates Human Hair Growth Researchers showed that the epithelium of human hair follicles, particularly the outer root sheath, expressed OR2AT4, and that specific stimulation of OR2AT4 by a synthetic sandalwood odorant prolonged human hair growth ex vivo by decreasing apoptosis and increasing production of the anagen-prolonging growth factor IGF-1. [Nat Commun] Full Article | Press Release | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DERMAL STEM CELLS & TISSUE REGENERATIONInvestigators showed collagen triple helix repeat containing 1 (Cthrc1) as a potential downstream effector of frizzled 6 (Fzd6), but not frizzled 3 (Fzd3). Cthrc1 bound directly to the extracellular domains of Fzd3 and Fzd6 to enhance Wnt/PCP signaling. [Development] Abstract Scientists showed that MUD1 exerted protective effects on human dermal fibroblasts, increasing cell viability and counteracted the oxidative stress promoted by 2,2′-azobis(2-amidinopropane) dihydrochloride-treatment, and improved mitochondria functionality and wound healing capacities. [Int J Mol Sci] Full Article SKIN CANCERS & DISORDERSYap Drives Cutaneous Squamous Cell Carcinoma Formation and Progression Investigators showed that human spindle cell carcinoma (spSCC) tumors featured strong nuclear localization of YAP and overexpression of activated YAP with keratin-5 was sufficient to induce rapid formation of both squamous cell carcinoma and spSCC in mice. [Elife] Full Article LMTK3 Is Essential for Oncogenic Kit Expression in Kit-Mutant Gist and Melanoma Researchers identified lemur tyrosine kinase 3 (LMTK3) and describe its role as a novel KIT regulator in KIT-mutant gastrointestinal stromal tumor (GIST) and melanoma cells. Silencing of LMTK3 decreased cell viability and increased cell death in KIT-dependent, but not KIT-independent GIST and melanoma cell lines. [Oncogene] Abstract In the presence of fibroblasts, melanoma cells switched to a dedifferentiated, mesenchymal-like, inflammatory phenotype that showed reduced sensitivity to most of 275 tested cancer drugs. Fibroblasts, however, sensitized melanoma cells to PI3K inhibitors and particularly the inhibitor of GSK3, AR-A014418, that showed superior efficacy in co-cultures. [Cancer Lett] Abstract Scientists revealed a down-regulation of glycolytic enzymes in cell lines and an up-regulation of amino acid metabolism enzymes in melanoma tumors, suggesting that TFAM may shift melanoma fuel utilization from glycolysis towards amino acid metabolism, especially glutamine. [Sci Rep] Full Article BRAF Inhibition Causes Resilience of Melanoma Cell Lines by Inducing the Secretion of FGF1 The authors showed in several melanoma cell lines that BRAF inhibition induced a secretome with a stimulating effect on fibroblasts and naive melanoma cells. They identified the growth factor FGF1 as a mediator of resilience towards BRAF inhibition, which limited the pro-apoptotic effects of the drug and activated fibroblasts to secrete HGF. [Oncogenesis] Full Article Researchers showed, that PI3K/AKT signaling via potent oncogenic PIK3CA and AKT3 mutants, was not sufficient to overcome proliferative arrest induced by BRAF/MEK inhibition, but rather enabled the survival of a dormant population of MAPK-inhibited melanoma cells. [Oncogenesis] Full Article The Role of PPARβ/δ in Melanoma Metastasis Investigators showed that 10h promoted epithelial-mesenchymal transition, migration, adhesion, invasion and trans-endothelial migration of mouse melanoma B16/F10 cells. [Int J Mol Sci] Full Article Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & Cancer Stem Cell News. | |
| |
| |
REVIEWSBeyond 2D: 3D Bioprinting for Skin Regeneration The authors summarize the various aspects of requirements related to well-suited 3D bioprinting techniques for skin regeneration and discuss how to overcome current bottlenecks and propel these therapies into the clinic. [Int Wound J] Abstract Visit our reviews page to see a complete list of reviews in the dermal cell research field. | |
| |
INDUSTRY NEWSPierre Fabre announced that the European Commission has granted marketing authorization for the combination of BRAFTOVI® and MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. [Pierre Fabre (Business Wire, Inc.)] Press Release Drug Combo for Advanced Skin Cancer Approved on NHS in England The National Institute for Health and Care Excellence has recommended giving the drugs, called dabrafenib and trametinib, to people after surgery if their stage 3 melanoma cells carry a certain genetic fault. Clinical trials have shown the combination treatment can reduce the risk of the disease coming back after surgery. [Cancer Research UK] Press Release AVITA Medical announced that the U.S. FDA approved the company’s Premarket Approval application to market the RECELL® Autologous Cell Harvesting Device to treat severe thermal burns in patients 18 years and older. [Avita Medical] Press Release DermTech Announces Enrollment Completion of Clinical Study to Assess DNA Damage and Reversal DermTech, Inc. announced it has completed enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potential of topical agents T4 endonuclease and photolyase to reduce DNA damage induced as measured through gene expression analysis. [DermTech, Inc. (Business Wire, Inc.)] Press Release | |
| |
POLICY NEWSReflecting the reluctance of the FDA to force drug makers to enroll more minority patients, and the failure of most manufacturers to do so voluntarily, stark underrepresentation of African-Americans is widespread in clinical trials for cancer drugs, even when the type of cancer disproportionately affects them. [STAT News] Editorial NSF Spells Out New Sexual Harassment Policy: Talk to Us Starting next month, universities must tell the National Science Foundation (NSF) in Alexandria, Virginia, if any faculty members with NSF grants have been found guilty of sexual and other forms of harassment, or if they have suspended them for any reason. But NSF won’t pull its funding if institutions can assure the agency that another faculty member can take over the research project. [ScienceInsider] Editorial Researchers Take Action to End Airlines’ Restrictions on Lab Animals In a recently filed complaint to the US Department of Transportation, the National Association for Biomedical Research accuses four major airlines of illegally discriminating against customers wishing to fly animals destined for the lab. [The Scientist] Editorial
| |
EVENTSNEW Stem Cells & Organoids in Development & Disease Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Chair – Melanoma Discovery (The University of Western Australia) Group Leader – Organoid Modeling of Disease (European Molecular Laboratory) Assistant Professor – Department of Biomedical Engineering (Boston University) Associate Researcher – Inflammatory Skin Diseases (Icahn School of Medicine at Mount Sinai) Postdoctoral Fellow – Skin Cancer (Stanford University School of Medicine) Post-doctoral Positions – Cancer Genetics/Genomics (University of Pennsylvania) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Dermal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
